Pfizer defends kidney-cancer position with Bavencio 'breakthrough'

The breakthrough designation is the second for Merck KGaA and Pfizer's Bavencio.

Pfizer has long expected immuno-oncology rivals to push aside its kidney cancer blockbuster, Sutent. But now, it’s getting in on the action with its own I-O product.

The FDA has bestowed its breakthrough designation on a combination of Bavencio—the PD-L1 cancer-fighter Pfizer shares with Merck KGaA—and its Sutent follow-up drug, Inlyta, in previously untreated renal cell carcinoma patients. The tag promises a speedy review of the pair.

RELATED: Bristol-Myers Squibb could double patient numbers for Opdivo in kidney cancer

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

It’s good news for Pfizer, which has already watched two other I-O meds top Sutent, the standard of care, in trials. In September, Bristol-Myers Squibb said that in a first-line trial, its Opdivo-Yervoy tandem had delivered a 32% reduction in the risk of death compared with Sutent. Among intermediate- and poor-risk patients, that number jumped to 37%.

More recently, Roche touted top-line data from a phase 3 study showing that a combination of PD-L1 therapy Tecentriq and anti-VEGF antibody Avastin could beat out Sutent at cutting the risk of patients' disease worsening or death by a "statistically significant and clinically meaningful" margin among patients whose tumors expressed PD-L1.

RELATED: Pfizer’s Sutent kidney cancer win should give it a boost, at least until I-O treatments arrive

Pfizer and Merck KGaA, for their parts, are still working through a phase 3 Bavencio-Inlyta trial, which should wrap up by the end of this year; the breakthrough boost comes based on phase 1b results, Pfizer said. The New York pharma giant, though, is expecting a strong performance.

“Pfizer’s expertise in developing treatments for advanced RCC is a distinct advantage in tackling this tumor type,” Chris Boshoff, SVP and head of Immuno-Oncology, Early Development and Translational Oncology, Pfizer Global Product Development, said in a statement.

RELATED: FDA puts Bristol-Myers' Opdivo-Yervoy combo in fast lane for new kidney cancer nod

For now, Sutent’s first-line patient pool is still intact. Opdivo is currently the only PD-1/PD-L1 contender approved in the disease at all, but it’s only indicated for previously treated patients. That could soon change, though: Last month, the FDA granted priority review status to Bristol’s Opdivo-Yervoy pairing.